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The primary role of osteoblasts is to lay down new bone during skeletal development and remodelling.
Throughout this process osteoblasts directly interact with other cell types within bone, including os-
teocytes and haematopoietic stem cells. Osteoblastic cells also signal indirectly to bone-resorbing os-
teoclasts via the secretion of RANKL. Through these mechanisms, cells of the osteoblast lineage help
retain the homeostatic balance between bone formation and bone resorption. When tumour cells dis-
seminate in the bone microenvironment, they hijack these mechanisms, homing to osteoblasts and
disrupting bone homeostasis. This review describes the role of osteoblasts in normal bone physiology, as
well as interactions between tumour cells and osteoblasts during the processes of tumour cell homing to
bone, colonisation of this metastatic site and development of overt bone metastases.
& 2016 The Author. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. The osteoblast in normal bone physiology
Under normal physiological conditions osteoblasts are re-
sponsible for the formation of new bone in the developing skele-
ton and during the process of bone remodelling. Osteoblasts arise
from the differentiation of mesenchymal cells committed to os-
teoprogenitors in the periosteum, via a process that requires se-
quential action of the transcription factors Runx2 and osterix [1].
These cells form closely packed sheets on the surface of bone from
which they extend cellular processes through the developing
bone. In order to successfully lay down new bone osteoblasts
produce a range of molecules, including enzymes, growth factors
and hormones such as, alkaline phosphatase, collagenase, TGF β,
IGFs, osteocalcin and type 1 collagen [1]. After the process of bone
formation, matrix synthesising osteoblasts have three potential
fates: Some osteoblasts become ﬂattened and remain as quiescent
lining cells at the bone surface and some die by apoptosis. How-
ever, with the deposition of new bone, the majority of osteoblasts
gradually become surrounded by the bone matrix and as the
matrix calciﬁes the cells (along with their associated cell products)
gets trapped inside the resulting lacunae. At this point cells of the
osteoblast lineage further differentiate into osteocytes [2,3]. Os-
teocytes communicate with each other as well as with osteoblasts,
via extensive cytoplasmic processes that occupy canaliculi within
the bone matrix. Both bone lining cells and osteocytes have been
identiﬁed as important sources of RANKL [4]. Thus, interactions
between RANKL from osteoblasts/osteocytes and RANK on osteo-
clasts directly affect osteoclastogenesis, regulating osteoclasticGmbH. This is an open access articbone resorption and the release of growth factors from the bone
matrix.2. Tumour cell homing and colonisation of bone
Bone is the third most common site for tumour cells to spread
and bone metastasis affects more than 600, 000 people every year
in the USA alone [5]. The site at which secondary tumours form is
not random; for metastases to develop tumour cells must arrive in
an environment that is permissive for their colonisation and
subsequent growth. In the case of bone metastasis it is hypothe-
sised that tumour cells home to speciﬁc niches: The endosteal
niche (which is primarily made up of osteoblasts), the haemato-
poietic stem cell (HSC) niche and the vascular niche (reviewed by
Maggague and Obenauf, 2016 and Weilbaecher, et al. 2011 [6–7]).
Evidence from in vivomodels suggest that all of these niches play a
role in tumour cell metastasis to bone and that interplay between
these niches determines whether tumour cells proliferate to overt
metastases or remain dormant.
2.1. The endosteal niche
In mouse models of breast and prostate cancer tumour cells
have been shown to home to areas in bone that have high num-
bers of osteoblasts and in breast cancer models chemical alteration
of the endosteal niche with zoledronic acid results in re-location of
tumour cells to new osteoblast rich areas of bone [8–9]. The
CXCR4/CXCL12 interaction is thought to be a key component in the
homing and adhesion of tumour cells to the metastatic niche in
bone. Osteoblasts express the chemokine CXCL12 whereas thele under the CC BY-NC-ND license
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corresponding receptor CXCR4. Once tumour cells have colonised
the endosteal niche evidence suggests that osteoblasts maintain
these tumour cells in a quiescent state, through the interactions of
CXCR4/CXCL12, using similar mechanisms to those used by os-
teoblasts for maintaining quiescence of HSCs [10].
2.2. The HSC niche
The HSC niche is also rich in CXCL12 and thus attracts CXCR4
positive tumour cells in the same way as the endosteal niche.
Convincing data from models of prostate cancer show when tu-
mour cells home to the HSC niche they compete with HSCs for
colonisation of this site [10–11]. Subsequent proliferation of tu-
mour cells out of the niche, enabling onset of overt metastases, is
thought to be facilitated by the mobilisation and proliferation of
HSCs and this process is likely to be supported by the vascular
niche [10–11].
2.3. The vascular niche
The close proximity of the vascular niche to the endosteal and
HSC niches in bone make it very difﬁcult to study these niches
independently in bone metastasis. Therefore, evidence that the
vascular niche plays a signiﬁcant role in metastasis primarily come
from models of brain metastasis: Observations made from breast,
lung and multiple myeloma cells that have metastasised to brain
demonstrate that following extravasation, within the metastatic
organ, cancer cells remain closely associated with the capillaries
[12–13]. These invading tumour cells spread along the basal la-
mina that surrounds the capillaries and proliferate, eventually,
engulﬁng and remodelling the capillary network [13].
Taken together, these data suggest that within bone, the en-
dosteal niche is responsible for maintaining tumour cells in a
quiescent state, whereas the HSC and vascular niches stimulate
proliferation to overt metastases. It is therefore likely that bone
turnover and bone cell activity are important regulators in sti-
mulating bone metastases from tumour cells seeded in this en-
vironment; a phenomenon that has long been observed in animal
models [14–15].3. Progression to overt metastases
When established in bone, cancer cells inﬂuence bone cells in
two predominant ways. Most often cancer cells stimulate the os-
teoclast lineage to increase osteoclast differentiation and activity
whilst simultaneously inhibiting osteoblasts [2]. When this hap-
pens, osteoclastic bone resorption exceeds osteoblastic bone for-
mation resulting in bone degradation and the formation of os-
teolytic lesions (common in breast, lung and multiple myeloma).
In some cases, instead of inhibiting osteoblasts, cancer cells release
substances to stimulate the osteoblast lineage to increase osteo-
blast differentiation and new bone deposition. When osteoblastic
bone formation exceeds osteoclastic bone resorption increased
bone growth results in 'bulges’ in the mineralised tissue where
tumour cells reside causing osteoblastic lesions. Because osteo-
blastic bone metastases is characterised by increases in both bone
resorption and bone formation lesions consist of weakened bone
with abnormal architecture and patients with this condition are at
increased risk of fracture (common in prostate) [16]. Although
more patients present with osteolytic lesions than osteoblastic the
distinction between the two-types is not absolute and many pa-
tients with bone metastasis have both osteolytic and osteoblastic
lesions [17]. Mechanistically, osteoclasts and osteoblasts play sig-
niﬁcant roles in the formation of both lesion types, however, thisarticle primarily focuses on osteoblasts. Evidence is emerging for a
direct role of osteoblasts on tumour growth in bone. In a mouse
model of breast cancer metastasis to bone, increasing the osteo-
blastic niche with PTH before intra-cardiac injection of human
breast cancer cells caused an increase in numbers of overt bone
metastases without altering tumour cell dissemination in bone
[18]. Pro-tumourigenic effects of PTH have also been observed in
rats treated with high doses of PTH [2]. However, in mouse models
of multiple myeloma, daily injection with PTH suppressed tumour
growth whilst increasing bone formation [19]. The effects of PTH
on tumour growth in bone, however, may not be solely due to
changes in osteoblasts. PTH treatment has profound affects upon
the bone microenvironment that go beyond increased osteoblast
numbers and activity. In all of the above studies PTH affected os-
teoclasts and it is likely that the gross morphological changes that
occur in bone, following this treatment, are accompanied by al-
terations to the vascular niche, although this hypothesis remains
to be explored. It has been suggested that osteoblasts and multiple
myeloma cells have inhibitory effects upon each other and in their
review Suvannasankha and Chirgwin hypothesise that these in-
hibitory effects may also occur between breast cancer cells and
osteoblasts [2]. The effects of osteoblasts on tumour growth and
progression to metastasis, therefore, warrants further
investigation.
3.1. Osteoblasts in osteolytic bone metastases
Tumour cells within the bone marrow can alter the function of
both osteoclasts and osteoblasts. In osteolytic bone metastases
tumour cells secrete factors that stimulate osteoclast activity
through the activation of the receptor activator of nuclear factor–
κB ligand (RANKL)/RANK pathway, which is a primary mediator of
osteoclast mediated bone resorption [17]. Additionally tumour
cells secrete factors that inhibit osteoblast differentiation and ac-
tivity including activin A, dickkopf-1 (DKK-1), sclerostin and
noggin [17]. Thus leading to an imbalance between bone resorp-
tion and bone formation resulting in increased bone destruction.
Increased bone resorption leads to a vicious cycle between tumour
cells and bone cells in which growth factors such as TGFβ and IGF
that were previously deposited in bone by osteoblasts are released
from resorption pits, stimulating tumour cell proliferation. The
tumour cells, in turn, produce more growth factors that stimulate
bone turnover [7]. TGFβ plays a central role in this process; release
of this molecule from bone directly stimulates tumour cells to
secrete PTHrP, which in turn induces bone RANKL [20–21]. Os-
teoblasts themselves also play a crucial role in initiation of bone
resorption since osteoblast precursor cells produce RANKL, which
stimulates osteoclast differentiation [22]. Initially, when tumours
are small, they induce an increase in osteoclast activity and
eliminate osteoblasts at the tumour/bone interface. To compensate
for this local elevation in bone resorption growth factors from the
resorbed bone stimulate osteoblast differentiation on the surface
of bone proximal to the tumour generating localised increase in
osteoclast stimulating RANKL [23]. At this point bone lesions de-
velop and the latter stages of disease are predominantly osteoclast
driven. Once osteolytic metastases are established in bone, the
release in TGFβ from resorption pits inhibits osteoblast differ-
entiation [17], ultimately resulting in the inhibition of new bone
formation thus contributing to the bone disease.
3.2. Osteoblastic bone metastases
A vicious cycle between tumour cells and bone cells also exists
for osteoblastic bone metastases (Fig. 1). In osteoblastic metastases
the vicious cycle observed in osteolytic disease still occurs, how-
ever, in addition to this tumour cells within bone produce
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Fig. 1. Vicious cycle of osteoblastic bone metastases. Diagrammatic representation of the interactions between tumour cells, osteoblasts and osteoclasts during the
processes of bone homing and colonisation in osteoblastic bone metastases.
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protein (BMP)s, epidermal growth factor (EGF)s and platelet de-
rived growth factor (PDGF). Tumour cells also secrete endothelin-1
(ET-1) which in turn downregulates (DKK-1) and stimulates os-
teoblatogenesis [24]. These activated osteoblasts produce factors
including IL-6, monocyte chemotactic protein-1 (MCP-1), VEGF,
and macrophage inﬂammatory protein 2 (MIP-2), which promote
further cancer cell colonisation and growth in the bone
environment.4. Future directions
There is increasing evidence that osteoblasts are important
components of the bone metastatic niche, but their precise con-
tribution in supporting tumour cell engraftment, dormancy and
survival remains to be deﬁned. Unlike osteoclasts, the role of os-
teoblasts in bone metastasis is relatively under-investigated. In-
creased understanding of how this cell type interacts with tumour
cells in the bone environment may be essential, if we are to
identify better therapeutic strategies for treating patients with this
condition. The potential importance of osteoblasts in therapies has
already been acknowledged with novel treatments aimed at tar-
geting bone formation already being put into clinical practise.
Traditional drugs such as bisphosphonates were developed to
target osteoclasts; however, these drugs also inhibit osteoblasts
[8,25]. Initial, laboratory testing indicated that targeting RANKL
may be more selective, reducing osteoclasts whilst increasing bone
formation, via increased differentiation of osteoblasts (reviewed
by Sims and Romas, 2015 [26]). However, when used in clinic, the
human RANKL inhibitor, denosumab inhibited serum bone re-
sorption and formation markers in women with osteoporosis [27].
It therefore seems likely that the close coupling of osteoclasts/
osteoblasts will make it impossible to use a single drug or a
combination of drugs at the same time point, to both resorb and
repair bone. It is also likely that osteoclast targeted therapies de-
signed to prevent progression of osteolytic lesions in bone are also
responsible for impaired healing and weakened bones seen in
myeloma patients after administration of these treatments [28]. It
is therefore proposed that a useful strategy to reverse bone loss
would be to turn on osteoblast functions. Evidence from patientswith multiple myeloma and lymphomas has demonstrated that
the proteasome inhibitors bortezomib and carﬁlzomib both pro-
mote bone formation by stimulating progenitor proliferation and
osteoblast differentiation. This drug is now FDA approved for pa-
tients with multiple myeloma and mantle cell lymphoma [2,29–
30]. Furthermore, proteasome inhibitors have also been shown to
prevent osteolytic lesion formation in pre-clinical models of breast
cancer bone metastasis [31]. These data indicate that targeting
osteoblasts in combination with osteoclast inhibition may provide
promising bone sparing agents for patients with bone metastases
[32]. However, it must also be noted that many drugs that have
bone anabolic effects including the proteasome inhibitors borte-
zomib, carﬁlzomib as well as antibodies that neutralise the WNT
inhibitors DKK1 and Sclerostin also have direct anti-tumour ef-
fects. It is, therefore, impossible to deduce whether these com-
pounds are exerting bone sparing effects or whether decreased
loss of bone is a side effect of reduced tumour burden [2,30].Unanswered questions1. Do osteoblasts play a part in both tumour cell homing and
progression in bone?
2. Can stimulating osteoblast activity result in repair of lytic bone
lesions?
3. Will osteoblast stimulating agents affect tumour growth in
bone; will these affects be tumour type speciﬁc?References
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